Alnylam Pharmaceuticals AAQS 2024
Alnylam Pharmaceuticals AAQS
7
Ticker
ALNY
ISIN
US02043Q1076
WKN
A0CBCK
Alnylam Pharmaceuticals has a current AAQS of 7.
A high AAQS can be seen as a positive indicator that the company is developing successfully.
Investors can assume that the company is on a good path to generate profits.
On the other hand, it is important to consider the AAQS of the stock Alnylam Pharmaceuticals in comparison to the profits generated and other companies in the same industry. A high AAQS is not an absolute guarantee for a positive future. Only in this way can one get a complete picture of the company's performance.
In order to better assess the company's development, it is important to consider the AAQS in comparison to other companies in the same industry. In general, investors should always consider the AAQS of a company in connection with other fundamentals such as profit, EBIT, cash flow, and others in order to make an informed investment decision.
Alnylam Pharmaceuticals Aktienanalyse
What does Alnylam Pharmaceuticals do?
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company specializing in the discovery, development, and commercialization of RNA-based therapeutics for the treatment of severe genetic and other diseases. The company was founded in 2002 by John Maraganore and Phillip Sharp and is headquartered in Cambridge, Massachusetts. Alnylam Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.Frequently Asked Questions about Alnylam Pharmaceuticals stock
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Alnylam Pharmaceuticals
Our stock analysis for Alnylam Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Alnylam Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
- Alnylam Pharmaceuticals Revenue
- Alnylam Pharmaceuticals Net Income
- Alnylam Pharmaceuticals P/E
- Alnylam Pharmaceuticals P/S
- Alnylam Pharmaceuticals EBIT
- Alnylam Pharmaceuticals Dividend
- Alnylam Pharmaceuticals Stocks
- Alnylam Pharmaceuticals Market capitalization
- Alnylam Pharmaceuticals Debt
- Alnylam Pharmaceuticals Liabilities
- Alnylam Pharmaceuticals Equity
- Alnylam Pharmaceuticals AAQS
- Alnylam Pharmaceuticals Employees
- Alnylam Pharmaceuticals ROE
- Alnylam Pharmaceuticals ROA
- Alnylam Pharmaceuticals ROCE